High-dose-rate brachytherapy in the treatment of carcinoma of the prostate

Cancer Control

Volumn 8, Issue 6, 2001, Pages 511-521

  Nisar Syed, A M ^a   Puthawala, Ajmel ^a   Sharma, Anil ^a   Gamie, Sherief ^a   Londrc, Adina ^a   Cherlow, Joel M ^a   Damore, Steven J ^a   Nazmy, Nashwa ^a   Sheikh, Khalid M ^b   Ko, Stephen J ^b  

^a LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRIDIUM 192;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; GASTROINTESTINAL TOXICITY; HUMAN; IMPLANT; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE; SCORING SYSTEM; SURGICAL TECHNIQUE; TREATMENT FAILURE; TUMOR VOLUME; URETHRA STRICTURE; URETHROTOMY; URINARY TRACT DISEASE; URINE INCONTINENCE;

EID: 0035693567     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800606     Document Type: Article

References (55)

1. Radical prostatectomy in the management of carcinoma of the prostate: Probable causes of some therapeutic failures
2. Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients
3. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for stage C adenocarcinoma of prostate
4. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer
5. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: A structured debate
6. Outpatient radical prostatectomy: Impact of standard perineal approach on patient outcome
7. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG phase III study for A2 and B prostate carcinoma
8. Status of radiation treatment of prostate cancer at Stanford University
9. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
10. Radical radiation therapy in the management of prostate adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome
11. Dose selection for prostate cancer patients based on dose comparison and dose response studies
12. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
13. Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10)
14. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
15. Role of beam orientation optimization in intensity-modulated radiation therapy
16. Particle beam radiation therapy in prostate cancer: Is there an advantage?
17. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
18. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
19. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
20. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial
21. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: Preliminary results
22. Retropubic implantation to iodine 125 in the treatment of prostatic cancer
23. Long-term results of retropubic permanent 125 iodine implantation of the prostate for clinically localized prostate cancer
24. Should brachytherapy be considered a therapeutic option in localized prostate cancer
25. Permanent prostate brachytherapy: The Arizona experience
26. Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques
27. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
28. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 1-125 prostate brachytherapy
29. The evolving role of prostate brachytherapy
30. Management of prostate carcinoma. Combination of pelvic lymphadenectomy, temporary Ir-192 implantation, and external irradiation
31. Temporary interstitial irradiation in the management of carcinoma of the prostate: Current status of a new approach
32. Treatment of prostatic carcinoma by pelvic lymphadenectomy, temporary Iridium-192 implant, and external irradiation
33. Temporary iridium-192 implant in the management of the prostate: An analysis of treatment results and complications in the first one hundred patients
34. Temporary iridium-192 implant in the management of carcinoma of the prostate
35. High dose-rate afterloading 192Iridium prostate brachytherapy: Feasibility report
36. High dose rate brachytherapy in the treatment of prostate cancer
37. Interim report of imageguided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont phase II dose-escalating trial
38. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer
39. High dose rate brachytherapy in the treatment of prostate cancer
40. Ultrasonically guided interstitial high dose rate brachytherapy with Ir-192: Technique and preliminary results in locally confined prostate cancer
41. High dose rate brachytherapy in the treatment of carcinoma of the prostate: Preliminary results
42. High dose rate interstitial brachytherapy in the treatment of localized carcinoma of the prostate: Analysis of biochemical response and complications
43. High dose rate treatment planning for prostate cancer implants using the Varisource remote afterloader
44. Needle displacement during HDR brachytherapy in the treatment of prostate cancer
45. Carcinoma of the prostate: Results of post-irradiation biopsy
46. The significance of post-irradiation prostate biopsy with long-term follow-up
47. The prognostic significance of post-irradiation biopsy results in patients with prostate cancer
48. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen
49. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography
50. Long term results of treatment for prostate cancer by staging pelvic lymph node dissection and definitive irradiation using low dose rate temporary iridium192 interstitial implant and external beam radiotherapy
51. Transperineal percutaneous iridium-192 interstitial template implant of the prostate: Results and complications in 321 patients
52. Bilateral pelvic lymphadenectomy, iridium 192 template, and external beam therapy for localized prostatic carcinoma: Complications and results
53. Brachytherapy boost techniques for locally advanced prostate cancer
54. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer
55. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma